Edition:
India

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Global Market

0.20USD
2:29am IST
Change (% chg)

$0.00 (+1.45%)
Prev Close
$0.20
Open
$0.20
Day's High
$0.21
Day's Low
$0.20
Volume
418,730
Avg. Vol
867,823
52-wk High
$5.65
52-wk Low
$0.13

Summary

Name Age Since Current Position

Hubert Birner

51 2005 Independent Chairman of the Board

Jeffrey Abbey

54 2010 President, Chief Executive Officer, Director

Richard Katz

53 2016 Chief Financial Officer, Vice President

Lori Harrelson

45 2011 Vice President - Finance

John Menditto

2015 Vice President - Corporate Communications & Investor Relations

Douglas Plessinger

46 2011 Vice President - Medical and Clinical Affairs

Charles Nicolette

53 2007 Vice President - Research & Development, Chief Scientific Officer

Robert Carey

58 2015 Director

Igor Krol

2016 Director

Richard Morrison

75 2017 Director

Irackly Mtibelishvily

2016 Director

Sander van Deventer

60 2013 Independent Director

Biographies

Name Description

Hubert Birner

Dr. Hubert Birner, Ph.D., is an Independent Chairman of the Board of Argos Therapeutics, Inc., since 2005. He was member of our board of directors since 2001. Dr. Birner joined the Munich office of TVM Capital, a venture capital firm and affiliate of ours, as an investment manager in 2000 and currently serves as the Managing Partner of the firm. From 1998 to 2000, Dr. Birner served as head of European business development and director of marketing for Germany at Zeneca Agrochemicals, a biopharmaceutical company. Prior to joining Zeneca Agrochemicals, Dr. Birner served as a management consultant in McKinsey & Company’s European healthcare and pharmaceutical practice. Dr. Birner has served on the board of directors of Proteon Therapeutics, Inc. since 2006 and of SpePharm Holdings BV since 2007. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, and Evotec AG. Dr. Birner received an M.B.A. from Harvard Business School and a doctorate in biochemistry from Ludwig-Maximilians University in Munich, Germany. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.

Jeffrey Abbey

Mr. Jeffrey D. Abbey is President, Chief Executive Officer, Director of Argos Therapeutics, Inc., since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010, including as our Vice President of Business Development from February 2004 to January 2009 and as our Chief Business Officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as Vice President of Business Development and Finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.

Richard Katz

Dr. Richard Katz, M.D. is Chief Financial Officer, Vice President of the Company. Prior to joining the Company, Dr. Katz was employed by Viamet Pharmaceuticals, Inc., a privately held biopharmaceutical company, as its Chief Financial Officer from February 2012 until May 2016. From April 2001 until November 2011, Dr. Katz served as an executive at Icagen, Inc., a publicly traded biopharmaceutical company (which was acquired by Pfizer), most recently as Executive Vice President, Finance and Corporate Development, Chief Financial Officer and Treasurer. From August 1996 to April 2001, Dr. Katz worked in the investment banking division of Goldman, Sachs & Co., an investment banking firm, most recently as a vice president in the healthcare group. Dr. Katz received his A.B. magna cum laude from Harvard University, his M.D. from the Stanford University School of Medicine and his M.B.A. from Harvard Business School, where he graduated as a Baker Scholar.

Lori Harrelson

Ms. Lori R. Harrelson is Vice President - Finance of Argos Therapeutics, Inc., since July 2011. Ms. Harrelson served as Director of Finance and Accounting from January 2007 to June 2011 and as Director of Accounting and Financial Reporting from September 2004 to January 2007. Prior to joining the company, she was Finance Manager at LipoScience, Inc., a diagnostic company, from 2001 to 2004. Ms. Harrelson received her B.S. in finance from East Carolina University and is a C.P.A.

John Menditto

Mr. John D. Menditto is Vice President - Corporate Communications & Investor Relations of the Company. Mr. Menditto comes to Argos with over 20 years of experience in the investor and corporate communications field. He has served as director, investor relations at Novartis Corporation and senior director at Medco Health Solutions. He has also spent a number of years as a communications consultant, including, more recently, as head of investor relations, The Americas, at the Imagination Group. He holds degrees in public relations and finance from Susquehanna University in Selinsgrove, Pennsylvania.

Douglas Plessinger

Mr. Douglas C. Plessinger is Vice President - Medical and Clinical Affairs of Argos Therapeutics, Inc., since October 2011. He served as a clinical consultant since October 2007 to 2011. Prior to joining us, Mr. Plessinger served as Executive Vice President and Managing Director at Axcelo MSL Solutions, LLC, an oncology consulting company, from August 2008 to September 2011 and founding partner and Managing Director of its predecessor company, venn5 BioConsulting, LLC, from 2007 to 2008. Prior to this, he served as Senior Vice President, Account Services at The Navicor Group, LLC, a healthcare advertising agency and a division of inVentiv Health, Inc., a healthcare services company, from 2004 to 2007; Oncology Medical Science Liaison at Millennium Pharmaceuticals, Inc., from 2002 to 2003; and in various Medical Affairs and Product Development roles at Bristol-Myers Squibb Oncology, a pharmaceutical company, from 1997 to 2002. Mr. Plessinger received a B.S. in pharmacy from Northeastern University.

Charles Nicolette

Dr. Charles A. Nicolette, Ph.D., is Vice President - Research & Development, Chief Scientific Officer of Argos Therapeutics, Inc., since December 2007. He was Vice President of Research and Development since December 2004. Dr. Nicolette served as our Vice President of Research from July 2003 to December 2004. Prior to joining us, Dr. Nicolette served in various positions at Genzyme Molecular Oncology, Inc., a biotechnology company, from 1997 to 2003, most recently as Director of Antigen Discovery. Dr. Nicolette received a B.S. from the State University of New York at Stony Brook and a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.

Robert Carey

Mr. Robert F. Carey, is Director of Argos Therapeutics, Inc. Currently serving as executive vice president and chief business officer for Horizon Pharma plc, Mr. Carey has more than three decades of experience in healthcare investment banking, business development and investor relations. He has served as an advisor on greater than $15 billion in financings, as well as numerous mergers and acquisitions. He was also responsible for starting and managing JMP Securities' healthcare group. Mr. Carey holds a BBA in accounting from the University of Notre Dame.

Igor Krol

Mr. Igor Krol is Director of the Company. Mr. Krol is affiliated with Pharmstandard International S.A., one of the Company’s principal stockholders and an investor under the previously disclosed Securities Purchase Agreement dated as of March 4, 2016.

Richard Morrison

Dr. Richard G. Morrison is Director of the company. He brings a wealth of pharmaceutical industry and financial expertise, as well as significant prior board level experience, to the Argos board of directors. Dr. Morrison spent the majority of his career at Eli Lilly, where he served for thirty years in a variety of international leadership roles, including president and general manager of Lilly's operations in Latin America. Prior to heading the Latin American companies, Dr. Morrison held several marketing and executive management positions in Europe, Africa and the Middle East, in both the pharmaceutical and agricultural divisions of the company. For three years during a period of very difficult macro-economics in Latin America, and certain other international markets, he lead a special group working to restructure the Lilly Latin American affiliates and operations, especially relating to organization and rationalization of manufacturing. This strategic work extended to Lilly Canada and Lilly Australia as well. Following his retirement from Eli Lilly in 1993, Dr. Morrison served on the faculty of the Cameron School of Business at the University of North Carolina Wilmington.

Irackly Mtibelishvily

Sander van Deventer

Dr., Sander J. H. van Deventer, M.D., Ph.D., is an Independent Director of Argos Therapeutics, Inc., since 2001. . van Deventer has been a General Partner of Forbion Capital Partners (formerly ABN AMRO Capital) since 2006. From 2008 to 2009, he served as the Chief Executive Officer of Amsterdam Molecular Therapeutics, or AMT, a gene therapy company that he co-founded in 1998. He has also served as a member of AMT’s board of directors since 2007. Dr. van Deventer has also served as a Professor of Translational Gastroenterology at Leiden University since 2008. He received an M.D. and Ph.D. from the University of Amsterdam.